{"schema_version":"secwatch.filing_event.v1","accession":"0000896622-26-000165","form_type":"8-K","ticker":"ATR","cik":"0000896622","company_name":"APTARGROUP, INC.","filed_at":"2026-07-30T21:19:26+00:00","discovered_at":"2026-07-30T21:20:00.343621+00:00","generated_at":"2026-07-30T21:20:08.529380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aptar Q2 sales top $1B; adjusted EPS $1.42; CEO Tanda to be succeeded by Touya on Sept 1","bullets":["Reported sales $1.03B (+6% reported, +1% core); reported EPS $1.36, adjusted EPS $1.42 (vs $1.68 prior year).","Pharma core +1% (high single-digit ex-emergency medicine); Beauty core +1%; Closures core +4%.","Adjusted EBITDA margin 20.7% vs 22.6% prior year; margins impacted by product mix and operational factors.","Q3 adjusted EPS guidance $1.45-$1.53; dividend $0.48/share payable Aug 20; $50M share repurchases in Q2.","CEO Stephan Tanda to retire; Gael Touya to become CEO effective Sept 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000896622-26-000165","json":"https://secwatch.observer/filing/0000896622-26-000165.json","markdown":"https://secwatch.observer/filing/0000896622-26-000165.md","text":"https://secwatch.observer/filing/0000896622-26-000165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896622/000089662226000165/0000896622-26-000165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896622/000089662226000165/atr-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T21:20:08.529380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}